A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Status:
Recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Phase 1

AstraZeneca